Sudhir Manda, MD on Proteasome Inhibition in MM: Who is Eligible?

Sudhir Manda, MD on Proteasome Inhibition in MM: Who is Eligible?

User Photo
Cancer-News

1 month
8 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Sudhir Manda, MD of Arizona Oncology discusses the long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib.
Up Next Autoplay